Hepion Pharmaceuticals, Inc. (HEPA)

USD 0.56

(0.61%)

Market Cap (In USD)

3.89 Million

Revenue (In USD)

-

Net Income (In USD)

-48.92 Million

Avg. Volume

155.13 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.478-3.72
PE
-
EPS
-
Beta Value
1.813
ISIN
US4268973025
CUSIP
426897104
CIK
1583771
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Patrick Brancaccio CPA
Employee Count
-
Website
https://www.hepionpharma.com
Ipo Date
2014-02-10
Details
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.